Enanta Pharmaceuticals | ENTA - Loan Capital


Enanta Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Biogen USD 7.29B 1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 28.42M 994K Jun/2026
Insmed USD 543.51M 1.3M Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
J&J USD 37.34B 183M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025